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Goals and Objectives
 Distinguish the etiologies and pathophysiology 
associated with the different WHO classification 
groups of pulmonary hypertension.
 Identify the pharmacological agents approved 
and under investigation for treatment of 
pulmonary arterial hypertension.
 Recognize the adverse drug reactions associated 
with the pharmacological agents used for 
treatment.





 Management of pulmonary arterial hypertension 
(PAH) (Group 1)
 Management of chronic thromboembolic 
pulmonary hypertension (CTEPH) (Group 4)







 Pulmonary hypertension (PH) is a disorder 
characterized by an increase in pulmonary artery 
pressure (PAP)
 Results from multifactorial pathophysiologic 
mechanisms with a wide variety in etiology
 Presentation can be nonspecific or attributed to 
comorbid conditions
Galiè N, et al. Eur Heart J. 2016;37:67-119.; Newman J. Am J Respir Crit Care Med. 2005;172(9):1072-1077.
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Epidemiology 
 Global reporting on the incidence of PH is limited 
 Around 1% of the global population suffers from PH
 PAH incidence levels range from 1.1 – 7.6 cases per 
one million per year; prevalence ranges from 6.6 –
26.0 cases per million per year
 CTEPH incidence rates are 0.9 cases per million per 
year; prevalence rates 3.2 cases per million per year
 The most common cause of PH is left heart disease 
(LHD)
Galiè N, et al. Eur Heart J. 2016;37:67-119.; Hoeper M, et al. Dtsch Arztebl Int. 2017;114: 73–84.; 










WHO Group 2:          
PH due to left 
heart disease
WHO Group 3:          




WHO Group 4:          





WHO Group 5:          




Adapted from: Lancet Respir Med 2016; 4:306–322.
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Conditions
 Group 1: PAH
 Idiopathic PAH (IPAH)
 Heritable
 Drugs and toxins
 Connective tissue disease
 Human immunodeficiency virus (HIV)
 Portal hypertension
 Congenital heart disease
 Schistosomiasis 
9
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Drugs and Toxins






Dexfenfluramine L-tryptophan St John’s Wort
Rapeseed oil Methamphetamines Amphetamine-
like drugs






Galiè N, et al. Eur Heart J. 2016;37:67-119.
Conditions
 Group 2: Left heart disease (LDH)
 Left ventricular systolic dysfunction
 Left ventricular diastolic dysfunction
 Valvular disease
 Congenital/acquired left heart inflow/outflow 
tract obstruction and congenital 
cardiomyopathies
 Congenital/acquired pulmonary veins 
stenosis
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Galiè N, et al. Eur Heart J. 2016;37:67-119.
Conditions
 Group 3: Lung disease/hypoxemia
 Chronic obstructive pulmonary disease
 Interstitial lung disease
 Other pulmonary diseases with mixed 
restrictive and obstructive pattern
 Sleep-disordered breathing
 Alveolar hypoventilation disorders
 Chronic exposure to high altitude
 Developmental lung diseases
12
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Conditions
 Group 4: Chronic thromboembolic 
pulmonary hypertension (CTEPH)
13
Galiè N, et al. Eur Heart J. 2016;37:67-119.
Conditions







Galiè N, et al. Eur Heart J. 2016;37:67-119.
Blood Flow Through the 
Cardiopulmonary Anatomy
 Vena Cava  Right Atrium  Right Ventricle 
Pulmonary Artery  Pulmonary Capillaries 
Pulmonary Vein  Left Atrium  Left Ventricle 





 PH: Elevation of pulmonary arterial pressure 
(PAPm) ≥ 25 mmHg at rest
 All groups 
 Pre-capillary PH: PAPm ≥ 25 mmHg and 
pulmonary arterial wedge pressure (PAWP) ≤ 15 
mmHg 
 Associated Groups: 1, 3, 4 & 5
 Post-capillary PH: PAPm ≥ 25 mmHg and PAWP > 
15 mmHg 
 Associated Groups: 2, 5















Toshner M, et al. Br Med Bull. 2010;94:21-32.
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3 Major Pathways  
↑ Endothelin-1
↑ binding on 













Endothelin Nitric Oxide Prostacyclin











 Symptoms are non-specific, initially induced by 
exertion: 
• shortness of breath, fatigue, weakness, angina and 
syncope
 Advanced Stages
 Abdominal distension, hepatomegaly, jugular 
venous pressure, edema 
 Presentation of PH may be modified by diseases 
that cause or are associated with PH as well as 
other concurrent diseases
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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Diagnosis



























PAPm ≥ 25 mmHg 
PAWP ≤ 15 mmHg 
Targeted Treatment?
WHO Group
Group 1 Pulmonary arterial 
hypertension
Yes
Group 2 Pulmonary hypertension due 
to left sided heart disease
No
Group 3 Pulmonary hypertension 
associated with lung disease 
or chronic hypoxemia
No
Group 4 Chronic thromboembolic
pulmonary hypertension and 
other pulmonary artery 
obstructions
Yes
Group 5 Pulmonary hypertension with 
unclear and/or multifactorial 
mechanism 
No






Evaluation of Disease 
Severity
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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World Health Organization Functional Classification (WHO-FC)
I • No resulting limitations of physical activity
• Ordinary physical activity does not cause undue fatigue or dyspnea, 
chest pain, or heart syncope
II • Slight limitation of physical activity
• Comfortable at rest
• Ordinary physical activity results in undue fatigue or dyspnea, chest 
pain, or heart syncope
III • Marked limitation of physical activity
• Comfortable at rest
• Less than ordinary physical activity causes undue fatigue or 
dyspnea, chest pain, or heart syncope
IV • Inability to carry on any physical activity without symptoms 
• Dyspnea/fatigue may be present at rest
• Physical activity increases discomfort
Adapted from: Eur Heart J. 2016;37:67-119
Evaluation of Disease 
Severity
Exercise capacity








• Right atrial pressure 
(RAP)
• Cardiac Index (CI)








Eur Heart J. 2016;37:67-119
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Prognosis
Determinant Low risk (<5%) Intermediate risk (5-10%) High risk (>10%)
Clinical signs of 
right heart failure Absent Absent Present
Progression of 
symptoms No Slow Rapid
Syncope No Occasional Repeated
WHO-FC I, II III IV
6MWD > 440 m 165 - 440 m < 165 m
Cardiopulmonary 
exercise testing




Peak VO2 11–15 ml/min/kg
(35-65 % predicted)
VE/VCO2 slope 36-44.9
Peak VO2 <11 
ml/min/kg
(<35 % predicted)
VE/VCO2 slope ≥ 36
Imaging RA area < 18 cm
2
No pericardial effusion
RA area 18 - 26 cm2
No or minimal pericardial effusion




CI ≥ 2.5 L/min/m2
SvO2 > 65 %
RAP 8-14 mmHg





Adapted from: Eur Heart J. 2016;37:67-119
PAH Treatment Goals 
 Maintain patients with in WHO-FC I-II
 Preserve 6MWT distance 
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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PAH Treatment
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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General Measures

























↓ binding on 



























Endothelin Nitric Oxide (NO) Prostacyclin

















WHO-FC II-III WHO-FC IV
Monotherapy Oral 











Oral calcium channel blockers dosing:
 Nifedipine 120–240 mg total daily dose (TDD)
 Diltiazem 240–720 mg  TDD
 Amlodipine 20 mg TDD
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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 Major vessel thromboembolism causes pulmonary 
artery remodeling
 CTEPH has been reported with a cumulative 
incidence of 0.1–9.1% within the first 2 years 
after asymptomatic pulmonary embolisms (PE) 
event
 Other pulmonary artery obstructions can also 
lead to remodeling
Galiè N, et al. Eur Heart J. 2016;37:67-119.
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CTEPH Treatment Goals 
 Remove obstructions
 Restore blood circulation in the lungs
Galiè N, et al. Eur Heart J. 2016;37:67-119.
33
CTEPH Treatment
• Pulmonary endarterectomy (PEA) is the treatment 
of choice
• Anticoagulants, diuretics, and O2 in cases of heart 
failure or hypoxemia
• Lifelong anticoagulation
• In symptomatic patients classified as having 
persistent/recurrent CTEPH after surgical 
treatment or with inoperable CTEPH, sCG 
stimulators are recommended








Medication Ambrisentan Bosentan Macitentan
Route Oral Oral Oral
Mechanism of Action In PAH ↑ endothelin-1 (ET-1) concentrations, action of ET-1 at ETA 
receptors causes vasoconstriction and cell proliferation. Action at 
ETB receptors causes vasodilation, antiproliferation, and ET-1 
clearance.
Blocks the action of 
ET-1 at ETA receptor
Blocks the action of ET-1 at ETA  and ETB
receptor
Warnings/Precautions • Pregnancy category X (REMs Programs)
• Not recommended in breast feeding
• Liver toxicity
• ↓ Hemoglobin
• ↓ Sperm counts
• Fluid retention
Tracleer [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2017; Letairis [prescribing 
information]. Foster City, CA:  Gilead Sciences, Inc; 2015; Opsumit [prescribing information]. South San Francisco, CA: Actelion 
Pharmaceuticals US, Inc; 2018
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Letairis® (ambrisentan)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise ability and delay clinical worsening
• Used in combination with tadalafil to reduce the risks of disease 
progression and hospitalization for worsening PAH and to improve 
exercise ability












Interactions • Cyclosporine (Max dose 5 mg)
Contraindications • Pregnancy 
• Idiopathic pulmonary fibrosis
Considerations • Medication guide & REMs requirement
• Tablets should not be split, crushed, or chewed 
FDA Approval 2007
Letairis [prescribing information]. Foster City, CA:  Gilead Sciences, Inc; 2015
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Tracleer® (bosentan)
Indication For treatment of PAH (WHO Group 1):
• Improves exercise ability and decreases clinical worsening
• In pediatric patients aged ≥3 yo with idiopathic or congenital PAH to improve 
pulmonary vascular resistance (PVR)
Initial Dose • ≤ 12 yo: 2 mg/kg PO BID
• > 12 yo & > 40 kg: 62.5 mg PO BID x 4wks, then 125 mg PO BID 











Interactions • Cyclosporine (contraindicated)
• Glyburide (contraindicated)
• Hormonal contraceptives
• CYP2C9 & CYP3A4 metabolites
Contraindications • Pregnancy 
• Use with Cyclosporine 
• Use with Glyburide 
• Hypersensitivity
Considerations • Medication guide & REMs requirement
• Available as film coated tablets and tablet for oral suspension
• Film coated tablets should not be split, crushed, or chewed 
• Missed doses should be taken ASAP unless the next dose is with in 6 hrs
FDA Approval 2001
Tracleer [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2017
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Opsumit® (macitentan)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Reduces risk of disease progression and hospitalization















Interactions • Strong CYP3A4 inhibitors and inducers
Contraindications • Pregnancy 
Considerations • Medication guide & REMs requirement
• Tablets should not be split, crushed, or chewed 
FDA Approval 2013
Opsumit [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2018
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Mechanism of Action • Stimulates sGC via a different binding site, independent of NO.
• Sensitizes sGC to endogenous NO by stabilizing the NO-sGC 
binding.
• Overall, it stimulates the NO-sGC-cGMP pathway and leads to 
increased generation of cGMP with subsequent vasodilation.
Warnings/Precautions • Symptomatic hypotension
• Bleeding
• Pulmonary edema (in veno-occlusive disease)
Adempas [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013
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Adempas® (riociguat)
Indication Treatment of adults with PAH (WHO Group 1):
• Improves exercise capacity, WHO functional class and to delays 
clinical worsening
Treatment of CTEPH (WHO Group 4) after surgical treatment or in 
inoperable CTEPH 
• Improves exercise capacity and WHO functional class
Initial Dose 1 mg PO TID
Adverse Drug 
Reactions (ADRs)
Headache, dyspepsia/gastritis, dizziness, nausea, diarrhea, hypotension, 
vomiting, anemia, gastroesophageal reflux, constipation, embryo-fetal
toxicity
Interactions • Strong CYP and PGP/BCRP inhibitors: consider a starting dose of 0.5 
mg PO TID
• Antacids: separate administration by 1 hr
Contraindications • Phosphodiesterase (PDE) inhibitors
Considerations • REMs requirement & medication guide
• Not recommended in breast feeding
• If therapy is missed for ≥3 days, restart at lower dose
FDA Approval 2013








Mechanism of Action • Inhibit PDE-5, preventing the breakdown of cGMP in smooth 
muscle cells
• Increased levels of cGMP induces vascular relaxation and 
vasodilation
Warnings/Precautions • Hearing impairment
• Vision impairment
• Pulmonary edema




Indication For treatment of PAH (WHO Group 1):
• Improves exercise ability and delays clinical worsening
Dosage • Tablet/suspension: 5 mg-20 mg PO TID
• Injection: 2.5 mg or 10 mg as IV bolus TID
Adverse Drug 
Reactions (ADRs)
Epistaxis, headache, dyspepsia, flushing, insomnia, erythema, dyspnea, rhinitis, 
priapism 
Interactions • Alpha blockers or amlodipine
• PDE-5 inhibitors
• CYP3A4 inhibitors (not recommended)
Contraindications • Use with nitrates
• Use with sCG stimulators
• Hypersensitivity
Considerations • Space doses 4-6 hours apart
• Available as 20 mg tablets, 10 mg/mL suspension, and 10 mg/12.5 mL single use
vial
FDA Approval 2005
Revatio [prescribing information]. New York, NY: Pfizer Labs; 2014
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Adcirca® (tadalafil) 
Indication For treatment of PAH (WHO Group 1):
• Improves exercise ability 
Dosage 40 mg PO daily
Adverse Drug 
Reactions (ADRs)
Headache, flushing, myalgia, erythema, rhinitis, priapism 
Interactions • Alpha blockers or amlodipine
• Alcohol
• PDE-5 inhibitors
• CYP3A4 inhibitors (not recommended)
• Use with ritonavir requires dose adjustments
Contraindications • Use with nitrates
• Use with sCG stimulators
• Hypersensitivity
Considerations • Available as 20 mg tablets
• Administered with out regard to meals
• Dividing dose over the course of the day is not recommended
FDA Approval 2009
Adcirca [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2017
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Prostacyclin Analogs










Mechanism of Action Analogs of endogenous prostacyclin (PGI2):
• Promote direct vasodilation of pulmonary vasculature 
• Inhibit platelet aggregation
Warnings/Precautions • Risk of rebound pulmonary hypertension, doses should not be discontinued or 
changed abruptly 
• Increased risk of bleeding
• Vasodilation reactions 
Flolan [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2018;
Veletri [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2012;
Ventavis [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2013;
Remodulin [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2018;
Tyvaso [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2016;
Orenitram [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2016;
Uptravi [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2017
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Flolan® (epoprostenol)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise capacity
Initial Dose • Initiate intravenous infusion through a central venous catheter at 2 
ng/kg/min
• Change dose in 1-to 2-ng/kg/min increments at intervals of at least 















Contraindications • Heart failure with reduced ejection fraction
• Hypersensitivity
Considerations • Diluent used (sterile diluent vs pH 12 sterile diluent) affects stability
• Reconstituted solutions may be used immediately; otherwise must be 
refrigerated
• Requires protection from light
• Requires infusion pump 
FDA Approval 1995
Flolan [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2018
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Veletri® (epoprostenol)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise capacity
Initial Dose • Initiate intravenous infusion through a central venous catheter at 2 
ng/kg/min
• Increments at intervals sufficient to allow assessment of clinical















Contraindications • Heart failure due to severe left ventricular systolic dysfunction
• Pulmonary edema
• Hypersensitivity
Considerations • Must be used at temperatures > 77° F – 104° F  
• Infusion rate calculation
• Requires protection from light
• Requires infusion pump 
FDA Approval 2008
Veletri [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2012
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Ventavis® (iloprost)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves composite endpoint consisting of exercise tolerance, NYHA 
Class, and lack of deterioration
Initial Dose • Starting dose: 2.5 mcg 
• Maintenance dose: 5 mcg


















Considerations • Requires use of I-neb® AAD® System
• Minimum of 2 hours between doses during waking hours
FDA Approval 2004
Ventavis [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2013
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Remodulin® (treprostinil)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Diminishes symptoms associated with exercise
• Reduces rate of clinical deterioration, in patients who require 
transition from Flolan
Initial Dose New to therapy:
• 1.25 ng/kg/min; increase based on clinical response (increments of 
1.25 ng/kg/min/wk x4 wks, then 2.5 ng/kg/min/wk)
Transition from Flolan:



















Considerations • Indicated for SC or IV use only as a continuous infusion
• Use central catheter for IV route
FDA Approval 2002
Remodulin [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2018
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Tyvaso® (treprostinil)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise ability
Initial Dose • Initial dosage: 3 breaths (18 mcg) per treatment session. If 3 breaths are not 
tolerated, reduce to 1 or 2 breaths


















Considerations • Use only with the Tyvaso® Inhalation System
• Administer undiluted, as supplied
• Separate sessions approximately four hours apart, during waking hours
• Sterile solution for oral inhalation available in 2.9 mL ampule containing 1.74 
mg treprostinil (0.6 mg per mL)
FDA Approval 2009
Tyvaso [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2016
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Orenitram® (treprostinil)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Improves exercise capacity
Initial Dose • Starting dose: 0.25 mg PO BID or 0.125 mg PO TID
• Titrate by 0.25 mg or 0.5 mg BID or 0.125 mg TID, not more than 
every 3 to 4 days as tolerated













Contraindications • Severe hepatic impairment (Child Pugh Class C)
Considerations • Give with food 
• Swallow tablet whole; use only intact tablets
• Available as extended-release tablets: 0.125 mg, 0.25 mg, 1 mg & 
2.5 mg
• Should not be taken with alcohol
• Never discontinue abruptly
FDA Approval 2013
Orenitram [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; 2016
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Uptravi® (selexipag)
Indication For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):
• Delays disease progression and reduces the risk of hospitalization
Initial Dose • Starting dose: 200 mcg PO BID
• Increase the dose by 200 mcg BID at weekly intervals to the highest 
tolerated dose up to 1600 mcg BID









• Pain in extremity
• Flushing
Severe
• Pulmonary edema 
Interactions • CYP2C8 inhibitors/inducers
Contraindications • Concomitant use with strong CYP2C8 inhibitors
Considerations • Tablet strengths: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 
1200 mcg, 1400 mcg, 1600 mcg
• Avoid use in severe hepatic impairment
• Not recommended in breastfeeding
FDA Approval 2015
Uptravi [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2017
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BPS-314d-MR Phase 3 study; BPS-314d-MR + inhaled treprostinil (Tyvaso) in PAH
• Beraprost sodium 314d modified release tablets
• Prostacyclin analog
Bardoxolone Methyl Phase 3 study, bardoxolone methyl + standard of care in patients with 
WHO Group 1 connective tissue disease PAH
• Bardoxolone methyl, activator of NRF2  decrease in oxidative 
damage
Ubenimex Phase 2 study; treatment of PAH
• Ubenimex, an oral inhibitor of LTA4H, the enzyme responsible for the 
formation of the pro-inflammatory mediator LTB4
CXA-10 Phase 2 study; CXA-10 + background therapy in PAH
• CXA-10, nitrated fatty acid compound with multiple mechanisms of 
action
ABI-009 Phase 1 study










True or False: 
 The World Health Organization (WHO) 
classification for pulmonary hypertension is 
delineated as follows: 
 Group 1 – Pulmonary Arterial Hypertension
 Group 2 – Pulmonary hypertension due to left 
sided heart disease (LHD)
 Group 3 – Pulmonary hypertension due to 
lung disease or hypoxia (or both)
 Group 4 – Pulmonary hypertension with 
unclear multifactorial mechanisms




True or False: 
 The World Health Organization (WHO) 
classification for pulmonary hypertension is 
delineated as follows: 
 Group 1 – Pulmonary Arterial Hypertension
 Group 2 – Pulmonary hypertension due to left 
sided heart disease (LHD)
 Group 3 – Pulmonary hypertension due to 
lung disease or hypoxia (or both)
 Group 4 – Pulmonary hypertension with 
unclear multifactorial mechanisms




 True or False: 
 Phosphodiesterase-5 inhibitors (PDE-5i) and 
soluble guanylate cyclase (sGC) stimulators 
are recommended for use as combination 




 True or False: 
 Phosphodiesterase-5 inhibitors (PDE-5i) and 
soluble guanylate cyclase (sGC) stimulators 
are recommended for use as combination 




 True or False: 
 The endothelin receptor antagonists 
ambrisentan, bosentan, and macitentan all 
have respective risk evaluation and mitigation 
strategy (REMS) programs due to the risk of 
causing embryo-fetal toxicity. 
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Test Questions:
 True or False: 
 The endothelin receptor antagonists 
ambrisentan, bosentan, and macitentan all 
have respective Risk Evaluation and Mitigation 
Strategy (REMS) programs due to the risk of 
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